New strategies to fabricate nanomedicines with high translational capacity are urgently desired. Herein, a new class of self-assembled drug cocktails that addresses the multiple challenges of manufacturing clinically useful cancer nanomedicines was reported.
Methods:
With the aid of a molecular targeted agent, dasatinib (DAS), cytotoxic cabazitaxel (CTX) forms nanoassemblies (
CD NAs
) through one-pot process, with nearly quantitative entrapment efficiency and ultrahigh drug loading of up to 100%.
Results:
Surprisingly, self-assembled
CD NAs
show aggregation-induced emission, enabling particle trafficking and drug release in living cells. In preclinical models of human cancer, including a patient-derived melanoma xenograft,
CD NAs
demonstrated striking therapeutic synergy to produce a durable recession in tumor growth. Impressively,
CD NAs
alleviated the toxicity of the parent CTX agent and showed negligible immunotoxicity in animals.
Conclusions:
Overall, this approach does not require any carrier matrices, offering a scalable and cost-effective methodology to create a new generation of nanomedicines for the safe and efficient delivery of drug combinations.